Pyxis Oncology, Inc. - PYXS Income before deduction of interest, taxes and amortization

Graphic logo of Pyxis Oncology Inc. (PYXS)

The base EBITDA reflects the financial dynamics of Pyxis Oncology, Inc. (PYXS), where the figure stands at 0.00. Demand for oncology drugs remains independent of economic cycles, rendering the company resistant to inflationary shocks. Efficiency is sustained by precision cold-chain logistics for biomaterials and the strategic expansion of the ADC conjugate portfolio to facilitate future partnerships with global pharma behemoths.

Profit before payment of interest, taxes and amortization: Pyxis Oncology, Inc. (PYXS) for 11/23/2025 - 11/12/2026

Pyxis Oncology - analytical breakdowns and key metrics (PYXS)

- market value and analyst target forecast:
Market Price Pyxis Oncology Inc.|PYXS - Consensus Target
- issuer market value details:
Market Value Pyxis Oncology|PYXS - Enterprise Value
- book capitalization information:
Net Assets per Share Pyxis Oncology|PYXS - Company Book Value|Market Cap to Net Assets Ratio pyxisoncology.com|PYXS - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Pyxis Oncology, Inc.|PYXS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Pyxis Oncology Inc.|PYXS - Company Debts|Debt to Book Value Ratio Pyxis Oncology|PYXS - Company Long-Term Debt|Short-Term Debt Pyxis Oncology|Critical Liquidity pyxisoncology.com
- company profitability and valuation multiples indicators:
PYXS - Net Income|Future Net Profit Pyxis Oncology, Inc.|PYXS - P/E Multiple|Future Price to Earnings Multiple Pyxis Oncology Inc.|PYXS - PEG Multiple|Company Value to EBITDA Pyxis Oncology|PYXS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Pyxis Oncology|PYXS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth pyxisoncology.com|PYXS - Earnings per share growth in current year|Net earnings per share change forecast for next year Pyxis Oncology, Inc.
Analysis of all company metrics:Pyxis Oncology, Inc. - PYXS
Mass-produced product of Pyxis Oncology

For the biotech sector of Pyxis Oncology, Inc. (PYXS), where value is created through patents and the development of cancer therapies, operating profit reflects the actual cash flow from core operations without the impact of depreciation or debt burdens. Analyzing the EBITDA size as of the current date allows investors to distinguish temporary dips from systemic liquidity deficits, warning them against buying a false bottom when there is a risk of long-term capital freeze.

Competitors of Pyxis Oncology, Inc. (PYXS)

NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization KA|NEXI (NexImmune) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Operating profit before deduction of amortization VCNX|Operating profit before amortization HARP (Harpoon Therapeutics Corp)